Preconditioning and cell-based therapeutics

David C Hess, MD Nasrul Hoda

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

One of the major barriers to cell therapy is the limited and often poor engraftment of stem and progenitor cells in tissues. The “potency” of transplanted cells can be increased by genetic modification or more easily by “preconditioning.” Preconditioning involves applying a sublethal stimulus to protect against a later lethal insult. One of the best-known and most feasible forms of preconditioning is “hypoxic preconditioning.” Stem cells normally reside in a “hypoxic” niche in the body. A large body of evidence demonstrates that hypoxic preconditioning of a wide variety of stem and progenitor cells prior to transplantation increases their survival and engraftment, increases their secretion of trophic and paracrine factors, stimulates tissue repair and remodeling, and facilitates functional recovery. Besides hypoxia, cytokines such as IL-6, drugs such as minocycline, and trophic factors such as stromal derived factor (SDF)-1 and erythropoietin also serve as “preconditioning” agents. Another approach is to “condition” the host tissue. A safe and feasible intervention, remote ischemic conditioning using a blood pressure cuff on the limbs, makes the host more receptive and responsive to transplanted cells, and should be further investigated in preclinical models.

Original languageEnglish (US)
Title of host publicationCell Therapy for Brain Injury
PublisherSpringer International Publishing
Pages173-186
Number of pages14
ISBN (Electronic)9783319150635
ISBN (Print)9783319150628
DOIs
StatePublished - Jan 1 2015

Fingerprint

Stem Cells
Tissue
Minocycline
Blood pressure
Thromboplastin
Erythropoietin
Stem cells
Interleukin-6
Repair
Cytokines
Recovery
Therapeutics
Pharmaceutical Preparations
Cell- and Tissue-Based Therapy
Extremities
Transplantation
Blood Pressure

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Neuroscience(all)

Cite this

Hess, D. C., & Hoda, MD. N. (2015). Preconditioning and cell-based therapeutics. In Cell Therapy for Brain Injury (pp. 173-186). Springer International Publishing. https://doi.org/10.1007/978-3-319-15063-5_11

Preconditioning and cell-based therapeutics. / Hess, David C; Hoda, MD Nasrul.

Cell Therapy for Brain Injury. Springer International Publishing, 2015. p. 173-186.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hess, DC & Hoda, MDN 2015, Preconditioning and cell-based therapeutics. in Cell Therapy for Brain Injury. Springer International Publishing, pp. 173-186. https://doi.org/10.1007/978-3-319-15063-5_11
Hess DC, Hoda MDN. Preconditioning and cell-based therapeutics. In Cell Therapy for Brain Injury. Springer International Publishing. 2015. p. 173-186 https://doi.org/10.1007/978-3-319-15063-5_11
Hess, David C ; Hoda, MD Nasrul. / Preconditioning and cell-based therapeutics. Cell Therapy for Brain Injury. Springer International Publishing, 2015. pp. 173-186
@inbook{d16498c77ea649aca33bac078134de47,
title = "Preconditioning and cell-based therapeutics",
abstract = "One of the major barriers to cell therapy is the limited and often poor engraftment of stem and progenitor cells in tissues. The “potency” of transplanted cells can be increased by genetic modification or more easily by “preconditioning.” Preconditioning involves applying a sublethal stimulus to protect against a later lethal insult. One of the best-known and most feasible forms of preconditioning is “hypoxic preconditioning.” Stem cells normally reside in a “hypoxic” niche in the body. A large body of evidence demonstrates that hypoxic preconditioning of a wide variety of stem and progenitor cells prior to transplantation increases their survival and engraftment, increases their secretion of trophic and paracrine factors, stimulates tissue repair and remodeling, and facilitates functional recovery. Besides hypoxia, cytokines such as IL-6, drugs such as minocycline, and trophic factors such as stromal derived factor (SDF)-1 and erythropoietin also serve as “preconditioning” agents. Another approach is to “condition” the host tissue. A safe and feasible intervention, remote ischemic conditioning using a blood pressure cuff on the limbs, makes the host more receptive and responsive to transplanted cells, and should be further investigated in preclinical models.",
author = "Hess, {David C} and Hoda, {MD Nasrul}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-15063-5_11",
language = "English (US)",
isbn = "9783319150628",
pages = "173--186",
booktitle = "Cell Therapy for Brain Injury",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Preconditioning and cell-based therapeutics

AU - Hess, David C

AU - Hoda, MD Nasrul

PY - 2015/1/1

Y1 - 2015/1/1

N2 - One of the major barriers to cell therapy is the limited and often poor engraftment of stem and progenitor cells in tissues. The “potency” of transplanted cells can be increased by genetic modification or more easily by “preconditioning.” Preconditioning involves applying a sublethal stimulus to protect against a later lethal insult. One of the best-known and most feasible forms of preconditioning is “hypoxic preconditioning.” Stem cells normally reside in a “hypoxic” niche in the body. A large body of evidence demonstrates that hypoxic preconditioning of a wide variety of stem and progenitor cells prior to transplantation increases their survival and engraftment, increases their secretion of trophic and paracrine factors, stimulates tissue repair and remodeling, and facilitates functional recovery. Besides hypoxia, cytokines such as IL-6, drugs such as minocycline, and trophic factors such as stromal derived factor (SDF)-1 and erythropoietin also serve as “preconditioning” agents. Another approach is to “condition” the host tissue. A safe and feasible intervention, remote ischemic conditioning using a blood pressure cuff on the limbs, makes the host more receptive and responsive to transplanted cells, and should be further investigated in preclinical models.

AB - One of the major barriers to cell therapy is the limited and often poor engraftment of stem and progenitor cells in tissues. The “potency” of transplanted cells can be increased by genetic modification or more easily by “preconditioning.” Preconditioning involves applying a sublethal stimulus to protect against a later lethal insult. One of the best-known and most feasible forms of preconditioning is “hypoxic preconditioning.” Stem cells normally reside in a “hypoxic” niche in the body. A large body of evidence demonstrates that hypoxic preconditioning of a wide variety of stem and progenitor cells prior to transplantation increases their survival and engraftment, increases their secretion of trophic and paracrine factors, stimulates tissue repair and remodeling, and facilitates functional recovery. Besides hypoxia, cytokines such as IL-6, drugs such as minocycline, and trophic factors such as stromal derived factor (SDF)-1 and erythropoietin also serve as “preconditioning” agents. Another approach is to “condition” the host tissue. A safe and feasible intervention, remote ischemic conditioning using a blood pressure cuff on the limbs, makes the host more receptive and responsive to transplanted cells, and should be further investigated in preclinical models.

UR - http://www.scopus.com/inward/record.url?scp=84943428895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943428895&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-15063-5_11

DO - 10.1007/978-3-319-15063-5_11

M3 - Chapter

AN - SCOPUS:84943428895

SN - 9783319150628

SP - 173

EP - 186

BT - Cell Therapy for Brain Injury

PB - Springer International Publishing

ER -